Two Sigma Advisers
EVOK

Two Sigma Advisers’s Evoke Pharma EVOK Stock Holding History

Two Sigma Advisers’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84
Closed -$22K – 2518
2021
Q1 		$22K Sell
84
-216
-72% -$86.4K ﹤0.01% 2520
2020
Q4 		$111K Buy
+300
New +$155K ﹤0.01% 2258

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers's EVOK Position: Q2 2021 in Review

Two Sigma Advisers sold out of Evoke Pharma (EVOK) in Q2 2021, closing a stake of 84 shares — an estimated $22K sold.

Two Sigma Advisers first reported a position in EVOK in Q4 2020 and held it in 2 quarters. The position peaked at $111K in Q4 2020. 19 funds tracked by Wall St. Rank hold EVOK as of Q2 2021.

  • Two Sigma Advisers reported no remaining Evoke Pharma position as of Q2 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 84 Evoke Pharma shares in Q2 2021, an estimated $22K.
  • Two Sigma Advisers first reported a position in Evoke Pharma in Q4 2020 and held it in 2 quarters.
  • Two Sigma Advisers's Evoke Pharma position peaked at $111K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2021.

Based on Two Sigma Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.